Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
SALT LAKE CITY - Molecular diagnostic testing company Myriad Genetics, Inc. (NASDAQ:MYGN), currently trading at $4.05 near its 52-week low of $3.81, has closed a five-year senior secured term loan credit facility providing up to $200 million from healthcare investment firm OrbiMed, according to a press release statement issued Thursday. According to InvestingPro data, the company has seen its stock decline over 85% in the past year.
The agreement includes $125 million in funded capital with an option to borrow an additional $75 million until June 30, 2027. The facility matures on July 31, 2030, and carries an interest rate based on the one-month secured overnight financing rate plus 6.50% per year, with a SOFR floor of 2.50% annually.
"Between this credit facility and our cash and cash equivalents, we now have access to more than $200 million in capital to support the company’s growth strategy," said Scott Leffler, chief financial officer at Myriad Genetics. The company, with a market capitalization of $373 million, maintains a healthy gross profit margin of 70% and a current ratio of 1.9. InvestingPro analysis indicates the stock is currently trading below its Fair Value.
Matthew Rizzo, General Partner of OrbiMed, stated, "We believe Myriad’s portfolio of diagnostic tests provide critical insights that enable healthcare providers to deliver better care to patients."
The new credit facility replaces Myriad’s previous ABL facility and is secured by substantially all assets of Myriad Genetics and its subsidiaries. Evercore served as exclusive financial advisor to Myriad Genetics on the transaction.
Myriad Genetics develops molecular tests across medical specialties where molecular insights can inform patient care, generating annual revenue of $831 million. OrbiMed is a healthcare investment firm with over $17 billion in assets under management. For deeper insights into Myriad Genetics’ financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, covering over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Myriad Genetics reported a revenue of $196 million for the first quarter of 2025, missing the forecast of $200.9 million. The company’s earnings per share also fell short of expectations, influenced by a $10 million negative impact due to a policy change by UnitedHealth Group. Following these financial results, Jefferies reduced Myriad Genetics’ stock price target to $5.00, maintaining an Underperform rating. Additionally, Scotiabank downgraded the stock from ’Sector Outperform’ to ’Sector Perform’ and slashed the price target to $6.00 from $20.00, citing concerns about the company’s near-term prospects. Analysts are particularly cautious about the company’s progress in its Oncology and Women’s Health segments. Piper Sandler, however, sees potential buying opportunities in dislocated Life Science stocks, including Myriad Genetics, despite the current market challenges. Piper Sandler believes these stocks could reset expectations to more achievable levels, appealing to small-cap value investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.